PMID- 15563743
OWN - NLM
STAT- MEDLINE
DCOM- 20050503
LR  - 20131121
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 20 Suppl 2
DP  - 2004
TI  - Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain 
      states: assessment with the Neuropathic Pain Scale.
PG  - S21-8
AB  - OBJECTIVE: To determine the impact of the lidocaine patch 5% on pain qualities 
      associated with chronic pain from postherpetic neuralgia (PHN), painful diabetic 
      neuropathy (DN), and low-back pain (LBP), using the Neuropathic Pain Scale (NPS). 
      PATIENTS AND METHODS: Patients with PHN, painful DN, and LBP were enrolled if 
      they had partial response to gabapentin-containing analgesic regimens and if they 
      reported moderate-to-severe pain on the NPS at study enrollment. Eligible 
      patients were included in an open-label, non-randomized, prospective, 2-week 
      study across 7 clinical trial sites in the United States. The lidocaine patch 5% 
      was applied to the area of maximal pain, using no more than a total of 4 patches 
      changed every 24 h. Patients were maintained on their other analgesic regimens 
      with no dose adjustment or additions allowed. Treatment effect was measured by 
      change from baseline to Week 2 in 4 composite measures of the NPS: NPS-10, NPS-4, 
      NPS-8, and NPS-non-allodynia. Safety was assessed by adverse events (AEs), dermal 
      assessment of application site(s), and skin sensory testing. RESULTS: In the 
      combined patient population (n = 77), 2 weeks of treatment with the lidocaine 
      patch 5% significantly improved all 4 composite measures (p < 0.01). In the 
      subgroup analyses, the lidocaine patch 5% demonstrated numerical advantage for 
      all 4 NPS composite measures for the PHN patients (n = 8), and significantly 
      improved all 4 composite measures for the painful DN patients (n = 41; p < 0.001) 
      and LBP patients (n = 28; p < or = 0.005). Overall, 8 patients (10%) experienced 
      mild-to-moderate treatment-related AEs. CONCLUSIONS: The lidocaine patch 5% 
      effectively reduces the intensity of all common pain qualities in patients with 
      moderate-to-severe chronic pain resulting from PHN, painful DN, or LBP. Treatment 
      is well tolerated in combination with other analgesic regimens, with no reports 
      of serious AEs or adverse drug interactions. Assessment scales such as the NPS 
      may offer the possibility to differentiate between various pain states and to 
      assess treatment outcomes for various pain qualities associated with a given pain 
      state.
FAU - Argoff, Charles E
AU  - Argoff CE
AD  - Cohn Pain Management Center, North Shore University Hospital/NYU School of 
      Medicine, Bethpage, NY 11714, USA. pargoff@optonline.net
FAU - Galer, Bradley S
AU  - Galer BS
FAU - Jensen, Mark P
AU  - Jensen MP
FAU - Oleka, Napoleon
AU  - Oleka N
FAU - Gammaitoni, Arnold R
AU  - Gammaitoni AR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Anesthetics, Local)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Administration, Cutaneous
MH  - Aged
MH  - Anesthetics, Local/*administration & dosage
MH  - Chronic Disease
MH  - Diabetic Neuropathies/complications
MH  - Female
MH  - Herpes Zoster/complications
MH  - Humans
MH  - Lidocaine/*administration & dosage
MH  - Low Back Pain/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neuralgia/*drug therapy/etiology
MH  - Pain Measurement/*methods
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Treatment Outcome
EDAT- 2004/11/27 09:00
MHDA- 2005/05/04 09:00
CRDT- 2004/11/27 09:00
PHST- 2004/11/27 09:00 [pubmed]
PHST- 2005/05/04 09:00 [medline]
PHST- 2004/11/27 09:00 [entrez]
AID - 10.1185/030079904X12960 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2004;20 Suppl 2:S21-8. doi: 10.1185/030079904X12960.